SEP 2022
2022 Drug Allergy Update
J Allergy Clin Immunol . 2022 Dec;150(6):1333-1393
David A Khan, Aleena Banerji, Kimberly G Blumenthal, Elizabeth J Phillips, Roland Solensky, Andrew A White, Jonathan A Bernstein, Derek K Chu, Anne K Ellis, David B K Golden, Matthew J Greenhawt, Caroline C Horner, Dennis Ledford, Jay A Lieberman, John Oppenheimer, Matthew A Rank, Marcus S Shaker, David R Stukus, Dana Wallace, Julie Wang; Chief Editor(s):; David A Khan, David B K Golden, Marcus Shaker, David R Stukus; Workgroup Contributors:; David A Khan, Aleena Banerji, Kimberly G Blumenthal, Elizabeth J Phillips, Roland Solensky, Andrew A White; Joint Task Force on Practice Parameters Reviewers:; Jonathan A Bernstein, Derek K Chu, Anne K Ellis, David B K Golden, Matthew J Greenhawt, Caroline C Horner, Dennis Ledford, Jay A Lieberman, John Oppenheimer, Matthew A Rank, Marcus S Shaker, David R Stukus, Dana Wallace, Julie Wang
Abstract
The primary focus of the drug allergy practice parameter historically has been to provide suggestions and recommendations for the proper diagnosis and management of the spectrum of drug hypersensitivity reactions (HSRs). Since the most recent update in 2010, which was a comprehensive review on the topic of drug allergy at the time, our understanding of several areas in the field has changed. This current update is a focused update on sections that the workgroup deemed to have significant changes from (or were not addressed in) the 2010 parameter. This update is not meant to be a comprehensive overview of drug hypersensitivity reactions as was the 2010 update, but rather this parameter is a focused update that will provide important suggestions and recommendations for the management of a variety of drug HSRs.
Click Below to Read the Full Publication
Supplemental Material
Drug Allergy: A 2022 Practice Parameter Update.ppt